enGene Holdings Inc. (NASDAQ:ENGN – Free Report) – HC Wainwright increased their Q3 2026 earnings estimates for shares of enGene in a report released on Tuesday, June 16th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.51) per share for the quarter, up from their previous estimate of ($0.56). HC Wainwright currently has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.97) per share. HC Wainwright also issued estimates for enGene’s Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($1.95) EPS, FY2027 earnings at ($2.00) EPS, FY2028 earnings at ($1.77) EPS, FY2029 earnings at ($0.77) EPS and FY2030 earnings at ($0.22) EPS.
ENGN has been the subject of several other reports. UBS Group reduced their price target on enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Wells Fargo & Company reiterated an “equal weight” rating and set a $2.00 price objective (down from $25.00) on shares of enGene in a research report on Friday, May 8th. Weiss Ratings downgraded enGene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 15th. Citigroup cut shares of enGene from a “market outperform” rating to a “market perform” rating in a research report on Friday, May 8th. Finally, Guggenheim lowered shares of enGene from a “buy” rating to a “neutral” rating in a research report on Thursday, May 7th. Four analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $11.05.
enGene Price Performance
enGene stock opened at $1.74 on Thursday. The company has a market capitalization of $116.56 million, a price-to-earnings ratio of -0.80 and a beta of -0.30. The company has a current ratio of 12.57, a quick ratio of 11.75 and a debt-to-equity ratio of 0.10. enGene has a 12 month low of $1.40 and a 12 month high of $12.25. The stock’s 50 day moving average is $4.10 and its 200-day moving average is $7.10.
enGene (NASDAQ:ENGN – Get Free Report) last released its quarterly earnings results on Monday, June 15th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.91. During the same quarter in the prior year, the firm earned $0.51 earnings per share.
Hedge Funds Weigh In On enGene
Hedge funds have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC raised its holdings in enGene by 179.8% in the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock valued at $52,998,000 after acquiring an additional 3,771,840 shares in the last quarter. Siren L.L.C. bought a new position in shares of enGene in the fourth quarter worth $30,126,000. Braidwell LP bought a new position in shares of enGene in the third quarter worth $15,479,000. Janus Henderson Group PLC acquired a new position in enGene in the fourth quarter valued at about $17,110,000. Finally, Cormorant Asset Management LP raised its stake in enGene by 72.1% in the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after purchasing an additional 1,676,405 shares in the last quarter. Institutional investors own 64.16% of the company’s stock.
Key Stories Impacting enGene
Here are the key news stories impacting enGene this week:
- Positive Sentiment: HC Wainwright kept a Buy rating on enGene Holdings Inc. (ENGN) and maintained a $4.00 price target, signaling continued analyst confidence in the stock. ENGN analyst coverage
- Positive Sentiment: The analyst improved earnings estimates for FY2026, Q3 2026, Q4 2026, FY2027, FY2028, and FY2029, suggesting losses may be narrowing faster than previously expected. ENGN estimate revisions
- Neutral Sentiment: HC Wainwright cut its FY2030 EPS estimate, which tempers the otherwise better near-term outlook. ENGN estimate revisions
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
See Also
- Five stocks we like better than enGene
- After an Initial Panic, Wall Street’s Leaning Into Apple’s New Siri AI
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
